That is stunningly speculative. Just because IPLEX launches, it does not follow that the PPS goes up.
It may, in fact, go down once costs associated with the launch vs revenues derived from product sales are fully realized. Furthermore, the lower their cash position goes (which it will if they burn on a product launch and clinical trial costs), they will once again be increasingly desperate for cash...on any terms.
Best scenario is when a small biotech can partner for codevelopment so that the partner's profits are ultimately made by the progresss and development of the product...not the gyrations or manipulations of the stock price.
News 
Market Data 
Discover 
